Shionogi will pay BioVersys $6.3 million for developing BV500, BioVersys's drug candidate for non-tuberculous mycobacteria.

Relative to before the pandemic, the number of vaccinated participants fell 10% among children and 4% in adults in pandemic ...

FDA vaccines chief Vinay Prasad limited broader use of COVID vaccines, citing reduced risk and data concerns. Read more here.

Rapid diagnostics continue transforming healthcare delivery worldwide, fueled by aging populations, decentralized care models, technological converge ...

The 2023 to 2024 COVID-19 vaccine provided additional effectiveness against medically attended COVID-19, according to a study published online June 24 in JAMA Network Open. Ruth Link-Gelles, Ph.D., M.

The use of TNF-α inhibitors among patients with hidradenitis suppurativa did not affect seroconversion following mRNA vaccination for COVID-19.

The University of Minnesota is stepping up efforts to identify biological threats that could trigger an epidemic, launching ...

The Indian Council of Medical Research (ICMR) and the National Institute of Epidemiology have conducted several studies in States and Union territories. India continues to carry a substantial burden, ...

In a comprehensive Genomic Press Innovators & Ideas interview, Dr. Danielle Beckman reveals how her passion for microscopy ...